Using an antiviral drug to enhance cancer treatment for melanoma
Novel Strategy to Augmenting Immunotherapy against Melanoma
This study is looking at how the antiviral drug nelfinavir might help boost the immune system's response to melanoma when combined with a special treatment called adoptive cell transfer, and melanoma patients may have a chance to join this exciting research to improve their therapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11045672 on NIH RePORTER |
What this research studies
This research investigates the use of nelfinavir, an antiviral medication, to improve the effectiveness of adoptive cell transfer (ACT) therapy for melanoma patients. The study aims to understand how nelfinavir can enhance the immune response against melanoma by targeting specific cellular mechanisms that affect T cell activity. By focusing on the role of a particular kinase involved in T cell function, the research seeks to develop a more effective treatment strategy for this aggressive form of skin cancer. Patients may have the opportunity to participate in trials that explore this innovative approach to immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma who may benefit from enhanced immunotherapy options.
Not a fit: Patients with non-melanoma skin cancers or those who are not eligible for ACT therapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using antiviral agents to enhance immunotherapy, suggesting that this approach could be a viable strategy.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Yang, Jin-Ming — University of Kentucky
- Study coordinator: Yang, Jin-Ming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.